Enliven Therapeutics, Inc. (ELVN) income statement
ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$46.41+1.52 (+3.39%)
Close on Nov 19, 2026Market cap $3.40BP/E –Yield –
Enliven Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -27.0%
Financial strength
- Current ratio
- 64.07
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 956.9%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.80
- Dividend yield
- –
See a number that looks wrong?